Translational research in genomics of Alzheimer's disease: A review of current practice and future perspectives

Journal of Alzheimer's Disease

Volumn 20, Issue 4, 2010, Pages 967-980

  Mihaescu, Raluca ^a   Detmar, Symone B ^b   Cornel, Martina C ^c   Van Der Flier, Wiesje M ^c   Heutink, Peter ^c   Hol, Elly M ^d   Rikkert, Marcel G M Olde ^e   Van Duijn, Cornelia M ^a   Janssens, A Cecile J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; genomics; review; translational research

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; BAPINEUZUMAB; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLATHRIN ASSEMBLY PROTEIN; CLOZAPINE; COMPLEMENT COMPONENT C3B RECEPTOR; CYSTATIN C; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GALANTAMINE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH HORMONE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PHOSPHATIDYLINOSITOL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PRESENILIN 1; PRESENILIN 2; PROGRANULIN; RISPERIDONE; ROSIGLITAZONE; SORTILIN; TAU PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; UNINDEXED DRUG; ZINC FINGER PROTEIN; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEALTH CARE MANAGEMENT; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; MEDICAL RESEARCH; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; FORECASTING; GENETICS; NEUROLOGY; TRANSLATIONAL RESEARCH; TRENDS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; EVIDENCE-BASED MEDICINE; FORECASTING; GENETIC TESTING; GENOMICS; GENOTYPE; HUMANS; NEUROLOGY; PRESENILIN-1; PRESENILIN-2; TRANSLATIONAL MEDICAL RESEARCH;

EID: 77954559377     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1410     Document Type: Review

References (94)

1. Alzheimer's Association (2009) 2009 Alzheimer's disease facts and figures. Alzheimers Dement 5, 234-270.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease I (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
3. Williamson J, Goldman JS, MayeuxR(2007) Genetic research and genetic testing in Alzheimer's disease: a view from the bridge. Nat Clin Pract Neurol 3, 356-357.
4. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL(2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168-174.
5. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 338, 506-511.
6. Green RC, Cupples LA,Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA, Group MS (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287, 329-336.
7. Van Der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76(Suppl 5), v2-v7.
8. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A (2000) Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S10-S15. (Pubitemid 30390599)
9. van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al. (1991) Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20(Suppl 2), S13-S20.
10. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, Group ADC (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105-2115.
11. Areosa SA, Sherriff F, McShane R (2005) Memantine for dementia. Cochrane Database Syst Rev, CD003154.
12. Cacabelos R (2008) Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 258(Suppl 1), 28-47.
13. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 175-193.
14. Riemersma-Van Der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ (2008) Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 299, 2642-2655.
15. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9, 665-674.
16. Bird TD (2008) Genetic aspects of Alzheimer disease. Genet Med 10, 231-239.
17. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706. (Pubitemid 21912142)
18. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
19. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
20. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
21. Alzheimer Disease & Frontotemporal Dementia Database, http://www.molgen.ua.ac.be/ADMutations, Accessed on October 6, 2009.
22. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, Levesque G, Rogaev EI, Lin C, Liang Y, Ikeda M, Mar L, Brice A, Agid Y, Percy ME, Clerget-Darpoux F, Piacentini S, Marcon G, Nacmias B, Amaducci L, Frebourg T, Lannfelt L, Rommens JM, St George-Hyslop PH (1996) Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5, 985-988. (Pubitemid 26232280)
23. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
24. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-VanceMA,Joo SH, Rosi BL, Gusella JF, Crapper- MacLachlan DR, Alberts MJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472. (Pubitemid 23230526)
25. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356.
26. Zuo L, van Dyck CH, Luo X, Kranzler HR,Yang BZ, Gelernter J (2006) Variation at APOE and STH loci and Alzheimer's disease. Behav Brain Funct 2, 13.
27. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC (2004) Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 6, 192-196.
28. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39, 17- 23. Last updated September 13, 2009, Accessed on October 7, 2009.
29. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J,Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65, 45-53.
30. Waring SC, Rosenberg RN (2008) Genome-wide association studies in Alzheimer disease. Arch Neurol 65, 329-334.
31. Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548-556.
32. Feldman HH, Jacova C, Robillard A, GarciaA, ChowT, Borrie M, Schipper HM, Blair M, Kertesz A, Chertkow H (2008) Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 178, 825-836.
33. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B, (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14, e1-e26.
34. Chertkow H (2008) Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ 178, 316-321.
35. Hsiung GYR, Sadovnick AD (2007) Genetics and dementia: Risk factors, diagnosis, and management. Alzheimers Dement 3, 418-427.
36. Verlinsky Y, Rechitsky S, Verlinsky O, Masciangelo C, Lederer K, Kuliev A (2002) Preimplantation diagnosis for earlyonset Alzheimer disease caused by V717L mutation. JAMA 287, 1018-1021.
37. Spriggs M (2002) Genetically selected baby free of inherited predisposition to early-onset Alzheimer's disease. J Med Ethics 28, 290.
38. Caselli RJ, Beach TG, Yaari R, Reiman EM (2006) Alzheimer's disease a century later. J Clin Psychiatry 67, 1784-1800.
39. Bonetta L (2008) Getting Up Close and Personal with Your Genome. Cell 133, 753-756.
40. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA (2009) Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 361, 245-254.
41. The Lancet N (2009) Genetic testing for disease susceptibility: a risky business. Lancet Neurol 8, 775.
42. Filley CM, Rollins YD, Alan Anderson C, Arciniegas DB, Howard KL, Murrell JR, Boyer PJ, Kleinschmidt-DeMasters BK, Ghetti B (2007) The genetics of very early onset Alzheimer disease. Cogn Behav Neurol 20, 149-156.
43. Randall CN, Strasburger D, Prozonic J, Morris SN, Winkie AD, Parker GR, Cheng D, Fennell EM, Lanham I, Vakil N, Huang J, Cathcart H, Huang R, Poduslo SE (2009) Cluster analysis of risk factor genetic polymorphisms in Alzheimer's disease. Neurochem Res 34, 23-28.
44. Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A (2008) Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer'saffected brain regions. Neuroimage 40, 1214-1221.
45. Licastro F, Porcellini E, Caruso C, Lio D, Corder EH (2007) Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 28, 1637-1643.
46. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, Nitsch RM, Hock C (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66, 940-947.
47. Corder EH, Huang R, Cathcart HM, Lanham IS, Parker GR, Cheng D, Smith S, Poduslo SE (2006) Membership in genetic groups predicts Alzheimer disease. Rejuvenation Res 9, 89-93.
48. Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, Green RC (2008) Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med 10, 207-214.
49. Schipper HM (2009) Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging, in press.
50. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12, 2762-2771.
51. Serretti A, Olgiati P, De Ronchi D (2007) Genetics of Alzheimer's disease. A rapidly evolving field. J Alzheimers Dis 12, 73-92.
52. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R (2005) Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 62, 975-980.
53. Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, Frolich L, Hampel H, Jolles J, Jones R, Minthon L, Nobili F, Olde Rikkert M, Ousset PJ, Rigaud AS, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B,Wahlund LO,Wilcock G,Winblad B (2008) Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. The DESCRIPA Study. Neuroepidemiology 30, 254-265.
54. Backman L, Small BJ (2007) Cognitive deficits in preclinical Alzheimer's disease and vascular dementia: patterns of findings from the Kungsholmen Project. Physiol Behav 92, 80-86.
55. Ray M, Zhang W (2009) Integrating gene expression and phenotypic information to analyze Alzheimer's disease. J Alzheimers Dis 16, 73-84.
56. Gupta M, Kaur H, Grover S, Kukreti R (2008) Pharmacogenomics and treatment for dementia induced by Alzheimer's disease. Pharmacogenomics 9, 895-903.
57. Van Der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, Van Der FlierWM(2007) Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord 24, 98-103.
58. Van Der Flier WM, Schoonenboom SN, Pijnenburg YA, Fox NC, Scheltens P (2006) The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 67, 526-527.
59. Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, Van Der Flier WM (2009) CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 16, 601-607.
60. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C (2007) Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8, 1735-1745.
61. Small GW (2006) Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 19, 180-185.
62. Chiappelli M, Tumini E, Porcellini E, Licastro F (2006) Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies. Expert Rev Neurother 6, 1327-1336.
63. Ryan J, Scali J, Carriere I, Ritchie K, Ancelin ML (2008) Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr 20, 47-56.
64. Ishunina TA, Swaab DF (2009) Hippocampal estrogen receptor-alpha splice variant TADDI in the human brain in aging and Alzheimer's disease. Neuroendocrinology 89, 187-199.
65. Craig MC, Maki PM, MurphyDG(2005) TheWomen's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 4, 190-194.
66. Burns A (2009) Alzheimer's disease: on the verges of treatment and prevention. Lancet Neurol 8, 4-5.
67. Masters CL, BeyreutherK(2006) Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129, 2823-2839.
68. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
69. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, For the Bapineuzumab 201 Clinical Trial I (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
70. Henderson ST,Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6, 31.
71. Candore G, Balistreri CR, Grimaldi MP, Listi F, Vasto S, Chiappelli M, Licastro F, Colonna-Romano G, Lio D, Caruso C (2007) Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach. Mech Ageing Dev 128, 67-75.
72. Heshka JT, Palleschi C, Howley H,Wilson B,Wells PS (2008) A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 10, 19-32.
73. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC, Group RS (2005) Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol 18, 250-255.
74. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, van Duijn CM (2006) Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 8, 395-400.
75. Janssens AC, Moonesinghe R, Yang Q, Steyerberg EW, van Duijn CM, Khoury MJ (2007) The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 9, 528-535.
76. Pomponi M, Bria P, PomponiM(2008) Is Alzheimer's disease a synaptic disorder? J Alzheimers Dis 13, 39-47.
77. Birks J, Grimley Evans J (2009) Ginko Biloba for cognitive impairment and dementia. Cochrane Database Syst Rev, CD003120.
78. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, St George-Hyslop PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB (1997) The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 277, 832-836.
79. Olde Rikkert MG, Van Der Vorm A, Burns A, Dekkers W, Robert P, Sartorius N, Selmes J, Stoppe G,Vernooij-Dassen M, Waldemar G (2008) Consensus statement on genetic research in dementia. Am J Alzheimers Dis Other Demen 23, 262-266.
80. Van Der Vorm A, Olde Rikkert MG, Vernooij-Dassen M, Dekkers W, Panel E (2008) Genetic research into Alzheimer's disease: a European focus group study on ethical issues. Int J Geriatr Psychiatry 23, 11-15.
81. St George-Hyslop P (2008) Genetics of dementia. Continuum Lifelong Learning Neurol 14, 29-48.
82. van Swieten JC, Heutink P (2008) Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 7, 965-974.
83. Thomas P, Fenech M (2007) A review of genome mutation and Alzheimer's disease. Mutagenesis 22, 15-33.
84. Coon KD, Myers AJ, CraigDW,Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M,Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68, 613-618.
85. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O'Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J (2007) Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16, 865-873.
86. Reiman EM,Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54, 713-720.
87. Webster JA, Myers AJ, Pearson JV, Craig DW, Hu-Lince D, Coon KD, Zismann VL, Beach T, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Huentelman MJ, Joshipura K, Walker D, Heward CB, Ravid R, Rogers J, Papassotiropoulos A, Hardy J, Reiman EM, Stephan DA (2008) Sorl1 as an Alzheimer's disease predisposition gene? Neurodegener Dis 5, 60-64.
88. Poduslo SE, Huang R, Huang J, Smith S (2009) Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B, 50-55.
89. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, Dowzell K, Cichon S, Hillmer AM, O'Donovan MC,Williams J, Owen MJ, KirovG(2008)Agenome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 1, 44.
90. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE (2008) Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83, 623-632.
91. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA (2009) Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 84, 35-43.
92. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N, Crook JE, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 41, 192-198.
93. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
94. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40, 124-125. Last updated September 28, 2009, Accessed on October 4, 2009.